ARQT

Arcutis Biotherapeutics, Inc.

8.09 USD
-0.01 (-0.12%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Arcutis Biotherapeutics, Inc. stock is down -0.49% since 30 days ago. The next earnings date is Aug 6, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 60% of the previous 4 June’s closed higher than May. In the last 10 Unusual Options Trades, there were 8 CALLs, 2 PUTs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
21 May 14:13 20 Sep, 2024 12.50 CALL 416 718
21 May 19:42 20 Sep, 2024 5.00 CALL 80 227
21 May 19:50 20 Sep, 2024 5.00 CALL 100 227
22 May 16:12 19 Jul, 2024 10.00 CALL 307 10
22 May 19:38 21 Jun, 2024 10.00 CALL 288 2374
23 May 14:19 20 Sep, 2024 12.50 CALL 259 1637
31 May 19:22 21 Jun, 2024 7.50 PUT 1000 9933
06 Jun 16:16 20 Sep, 2024 7.50 CALL 1350 341
07 Jun 15:21 21 Jun, 2024 10.00 PUT 196 3023
10 Jun 13:54 20 Sep, 2024 7.50 CALL 354 1727

About Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of arq-154.

  • Needham
    Wed May 15, 11:50
    buy
    confirm
  • Mizuho
    Wed May 15, 07:08
    buy
    confirm